PROTALIX BIOTHERAPEUTICS INC (PLX)       1.62  -0.01 (-0.61%)

1.62  -0.01 (-0.61%)

US74365A3095 - Common Stock - After market: 1.6 -0.02 (-1.23%)

News Image
2 months ago - TheNewswire.com

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease.

News Image
5 months ago - TheNewswire.com

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a company by looking at how options traders are trading it.

News Image
10 months ago - Market News Video

Thursday 4/14 Insider Buying Report: PLX, HCP

News Image
a year ago - PennyStocks.com

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

5 penny stocks with high short interest to add to your watch list in December.

News Image
1 years ago - Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Private Note Exchange

News Image
1 years ago - Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021

Company to host conference call and webcast at 8:30 a.m. EDT